Turnstone Biologics is engaged in the development of medicines to treat and cure patients with solid tumors. Co. is developing a differentiated approach to tumor infiltrating lymphocyte (TIL) therapies by selecting the potent, which able to mediate an anti-tumor response and tumor-reactive T cells. Co. has initiated two Phase 1 clinical trials for its Selected TIL product candidate, TIDAL-01, for the treatment of breast cancer, colorectal cancer, uveal melanoma and other non-cutaneous and cutaneous melanomas. Co. also advances on its preclinical pipeline programs including TIDAL-02, next Selected TIL program and TIDAL-01 viral immunotherapy combination program. The TSBX average annual return since 2023 is shown above.
The Average Annual Return on the TSBX average annual return since 2023 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether TSBX average annual return since 2023 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the TSBX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|